Jacobs Levy Equity Management
PRAX icon

Jacobs Levy Equity Management’s Praxis Precision Medicines PRAX Stock Holding History

Jacobs Levy Equity Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,140
Closed -$2.99M – 1044
2025
Q4 		$2.99M Sell
10,140
-3,758
-27% -$700K 0.01% 518
2025
Q3 		$737K Sell
13,898
-31,184
-69% -$1.51M ﹤0.01% 770
2025
Q2 		$1.9M Buy
45,082
+5,083
+13% +$194K 0.01% 628
2025
Q1 		$1.51M Hold
39,999
– – 0.01% 722
2024
Q4 		$3.08M Hold
39,999
– – 0.01% 519
2024
Q3 		$2.3M Sell
39,999
-23,362
-37% -$1.26M 0.01% 577
2024
Q2 		$2.62M Buy
63,361
+11,813
+23% +$558K 0.01% 560
2024
Q1 		$3.15M Sell
51,548
-14,940
-22% -$670K 0.01% 515
2023
Q4 		$1.48M Buy
66,488
+20,929
+46% +$377K 0.01% 655
2023
Q3 		$1.17M Sell
45,559
-41,609
-48% -$787K 0.01% 648
2023
Q2 		$1.5M Buy
+87,168
New +$1.33M 0.01% 623
2023
Q1 		– Sell
-16,801
Closed -$600K – 1046
2022
Q4 		$600K Sell
16,801
-1,002
-6% -$31.2K ﹤0.01% 760
2022
Q3 		$606K Buy
+17,803
New +$887K ﹤0.01% 804

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jacobs Levy Equity Management's PRAX Position: Q1 2026 in Review

Jacobs Levy Equity Management sold out of Praxis Precision Medicines (PRAX) in Q1 2026, closing a stake of 10,140 shares — an estimated $2.99M sold.

Jacobs Levy Equity Management first reported a position in PRAX in Q3 2022 and held it in 13 quarters. The position peaked at $3.15M in Q1 2024. 291 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Jacobs Levy Equity Management reported no remaining Praxis Precision Medicines position as of Q1 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 10,140 Praxis Precision Medicines shares in Q1 2026, an estimated $2.99M.
  • Jacobs Levy Equity Management first reported a position in Praxis Precision Medicines in Q3 2022 and held it in 13 quarters.
  • Jacobs Levy Equity Management's Praxis Precision Medicines position peaked at $3.15M in Q1 2024.
  • 291 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.